Hasil Pencarian - Xinmin Yu

  • Menampilkan 1 - 12 hasil dari 12
Perbaiki Hasil
  1. 1
    Chemotherapy and prognosis in advanced thymic carcinoma patients

    Chemotherapy and prognosis in advanced thymic carcinoma patients oleh Zhengbo Song, Xinmin Yu, Yiping Zhang

    Diterbitkan 2015-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report

    Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report oleh Qiong He, Xinmin Yu, Junrong Yan, Xun Shi, Hongming Pan

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

    Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer oleh Chen Lin, Chen Lin, Chen Lin, Xun Shi, Xun Shi, Xun Shi, Jun Zhao, Jun Zhao, Jun Zhao, Qiong He, Qiong He, Qiong He, Yun Fan, Yun Fan, Yun Fan, Weizhen Xu, Weizhen Xu, Yang Shao, Xinmin Yu, Xinmin Yu, Xinmin Yu, Xinmin Yu, Ying Jin, Ying Jin, Ying Jin, Ying Jin

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Chloride Ion Penetration Resistance of Reactive Powder Concrete with Mineral Admixtures

    Chloride Ion Penetration Resistance of Reactive Powder Concrete with Mineral Admixtures oleh Xinmin YU, Hongji ZHANG, Dehong WANG, Yanzhong JU, Mengxin KANG, Yidan MA

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

    Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib oleh Ying Jin, Chen Lin, Xun Shi, Qiong He, Junrong Yan, Xinmin Yu, Ming Chen

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A Low-Hydroxyl Quartz Glass Prepared by Using a Plasma Heat Source as the Flame and High-Purity Quartz Sand as the Raw Material

    A Low-Hydroxyl Quartz Glass Prepared by Using a Plasma Heat Source as the Flame and High-Purity Quartz Sand as the Raw Material oleh Xinmin Yu, Xiurong Du, Xuefu Song, Yongchang Zhu, Xing Liu, Lisheng Zhou, Xueyi Zhu, Kai Qiu

    Diterbitkan 2024-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified

    Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified oleh Yiping ZHANG, Beibei ZHANG, Chunxiao HE, Baochai LIN, Lan SHAO, Jufen CAI, Xinmin YU, Zhengbo SONG

    Diterbitkan 2013-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

    Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lu... oleh Wenxian Wang, Wenxian Wang, Zhangzhou Huang, Zongyang Yu, Wu Zhuang, Weijun Zheng, Zhijian Cai, Lei Shi, Xinmin Yu, Xinmin Yu, Guangyuan Lou, Guangyuan Lou, Wei Hong, Wei Hong, Yiping Zhang, Yiping Zhang, Ming Chen, Zhengbo Song, Zhengbo Song

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

    Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy oleh Jing Wang, Jie Liu, Yan Zhang, Hua Zhong, Xinmin Yu, Lijuan Chen, Xueyan Zhang, Panwen Tian, Tianqing Chu, Qisen Guo, Zhuang Yu, Yalun Li, Yan Guan, Xun Shi, Yanqiu Zhao, Baohui Han

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

    Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study oleh Yuankai Shi, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, Yutao Liu, Dingzhi Huang, Tianshu Liu, Hong Shen, Suxia Luo, Hongsheng Yu, Yu Cao, Xi Zhang, Pei Hu

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

    SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer oleh Hui Li, Mark Voskoboynik, Qing Zhou, Hongming Pan, Juan Zhang, Yi-Long Wu, Bo Gao, Jun Zhao, Yunpeng Liu, Qian Chu, Lifeng Wang, Jiuwei Cui, Daphne Day, Xinmin Yu, Dingzhi Huang, Zhiyong Ma, Meili Sun, Jingxun Wu, Zhehai Wang, Yanyan Peng

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

    Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)... oleh Yuankai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Caicun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Ying Yuan, Jifeng Feng, Zhendong Chen, Jindong Shi, Tao Sun, Gang Wu, Yongqian Shu, Qisen Guo, Yi Zhang, Yong Song, Shucai Zhang, Yuan Chen, Wei Li, Hongrui Niu, Wenwei Hu, Lijun Wang, Jianan Huang, Yang Zhang, Ying Cheng, Zhengdong Wu, Bo Peng, Jiya Sun, Christoph Mancao, Yanqi Wang, Luyao Sun

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: